Billions in Healthcare Costs Caused by Infections from Multi-Drug Resistant Bacteria

A new study published in Clinical Infectious Diseases, reports estimates of healthcare costs associated with infections due to multidrug-resistant bacteria in the United States. Antimicrobial-resistant infections lead to substantial healthcare costs extrapolated to annual national costs exceeding $4.6 billion.

This is one of the largest studies to estimate the attributable cost associated with 6 high-priority antibiotic-resistant pathogens:

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Extended-spectrum cephalosporin resistance in Enterobacteriaceae suggestive of extended-spectrum β-lactamase (ESBL) production
  • Vancomycin-resistant Enterococcus (VRE)
  • Carbapenem-resistant Acinetobacter species (CRAsp)
  • Carbapenem-resistant Enterobacteriaceae (CRE)
  • Multidrug-resistant (MDR) Pseudomonas aeruginosa.
Wound Care - JMeds
These estimates underscore the importance of efforts to reduce transmission of antibiotic-resistant pathogens in hospitals which could include methods to improve hand hygiene adherence, improved surveillance and patient isolation techniques, or antimicrobial stewardship programs.

JMeds TruSafe™

JMeds has the tools to help you prevent the spread of infection in your facility.

Contact Us

133 Nursery Lane
Fort Worth, Texas 76114
877.790.5994

Subscribe to JMeds News

* indicates required

JMeds is a Kalos Health Services company. Kalos Health Services, LLC., is a pioneer in healthcare management and services. All product names, logos, and brands are property of their respective owners.

Privacy Policy | Terms of Use

Site design by Teleos Marketing.